RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates

Nucleic Acids Research

Volumn 43, Issue 19, 2015, Pages 9434-9445

  Polevoda, Bogdan ^a   McDougall, William M ^a,c   Tun, Bradley N ^a   Cheung, Michael ^a   Salter, Jason D ^b   Friedman, Alan E ^a,d   Smith, Harold C ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b OyaGen Inc   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3G PROTEIN, HUMAN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; PEPTIDE; PROTEIN BINDING; RNA; SINGLE STRANDED DNA;

BINDING COMPETITION; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR MODEL;

ALLOSTERIC SITE; APOBEC-3G DEAMINASE; BINDING SITES; BINDING, COMPETITIVE; CYTIDINE DEAMINASE; DNA, SINGLE-STRANDED; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; RNA;

EID: 84959422349     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv970     Document Type: Article

References (70)

1. Sheehy,A.M., Gaddis,N.C., Choi,J.D. and Malim,M.H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.
2. Smith,H.C. (2011) APOBEC3G: a double agent in defense. Trends Biochem. Sci., 36, 239-244.
3. Harris,R.S., Bishop,K.N., Sheehy,A.M., Craig,H.M., Petersen-Mahrt,S.K., Watt,I.N., Neuberger,M.S. and Malim,M.H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell, 113, 803-809.
4. Chelico,L., Pham,P., Calabrese,P. and Goodman,M.F. (2006) APOBEC3G DNA deaminase acts processively 3′ - > 5′ on single-stranded DNA. Nat. Struct. Mol. Biol., 13, 392-399.
5. Yu,Q., Konig,R., Pillai,S., Chiles,K., Kearney,M., Palmer,S., Richman,D., Coffin,J.M. and Landau,N.R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol., 11, 435-442.
6. Suspene,R., Rusniok,C., Vartanian,J.P. and Wain-Hobson,S. (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res., 34, 4677-4684.
7. Holmes,R.K., Malim,M.H. and Bishop,K.N. (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci., 32, 118-128.
8. Soros,V.B., Yonemoto,W. and Greene,W.C. (2007) Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog., 3, e15.
9. Friew,Y.N., Boyko,V., Hu,W.S. and Pathak,V.K. (2009) Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology, 6, 56-86.
10. Bogerd,H.P. and Cullen,B.R. (2008) Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA, 14, 1228-1236.
11. Svarovskaia,E.S., Xu,H., Mbisa,J.L., Barr,R., Gorelick,R.J., Ono,A., Freed,E.O., Hu,W.S. and Pathak,V.K. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem., 279, 35822-35828.
12. Burnett,A. and Spearman,P. (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol., 81, 5000-5013.
13. Wang,T., Tian,C., Zhang,W., Luo,K., Sarkis,P.T., Yu,L., Liu,B., Yu,Y. and Yu,X.F. (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol., 81, 13112-13124.
14. Huthoff,H. and Malim,M.H. (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol., 81, 3807-3815.
15. Alce,T.M. and Popik,W. (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem., 279, 34083-34086.
16. Bach,D., Peddi,S., Mangeat,B., Lakkaraju,A., Strub,K. and Trono,D. (2008) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology, 5, 54.
17. Chelico,L., Pham,P. and Goodman,M.F. (2009) Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat. Struct. Mol. Biol., 16, 454-456.
18. Gaddis,N.C., Chertova,E., Sheehy,A.M., Henderson,L.E. and Malim,M.H. (2003) Comprehensive Investigation of the Molecular Defect in vif-Deficient Human Immunodeficiency Virus Type 1 Virions. J. Virol., 77, 5810-5820.
19. Sheehy,A.M., Gaddis,N.C. and Malim,M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med., 9, 1404-1407.
20. Zhang,W., Du,J., Evans,S.L., Yu,Y. and Yu,X.F. (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature, 481, 376-379.
21. Jager,S., Kim,D.Y., Hultquist,J.F., Shindo,K., LaRue,R.S., Kwon,E., Li,M., Anderson,B.D., Yen,L., Stanley,D. et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature, 481, 371-375.
22. Conticello,S.G., Harris,R.S. and Neuberger,M.S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol., 13, 2009-2013.
23. Kreisberg,J.F., Yonemoto,W. and Greene,W.C. (2006) Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med., 203, 865-870.
24. Chiu,Y.L., Witkowska,H.E., Hall,S.C., Santiago,M., Soros,V.B., Esnault,C., Heidmann,T. and Greene,W.C. (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A., 103, 15588-15593.
25. Prohaska,K.M., Bennett,R.P., Salter,J.D. and Smith,H.C. (2014) The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions. Wiley Interdisciplinary Rev. RNA, 5, 493-508.
26. McDougall,W.M. and Smith,H.C. (2011) Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity. Biochem. Biophys. Res. Commun., 412, 612-617.
27. Gallois-Montbrun,S., Kramer,B., Swanson,C.M., Byers,H., Lynham,S., Ward,M. and Malim,M.H. (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol., 81, 2165-2178.
28. Wichroski,M.J., Robb,G.B. and Rana,T.M. (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog., 2, e41.
29. Apolonia,L., Schulz,R., Curk,T., Rocha,P., Swanson,C.M., Schaller,T., Ule,J. and Malim,M.H. (2015) Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog., 11, e1004609.
30. Strebel,K. and Khan,M.A. (2008) APOBEC3G encapsidation into HIV-1 virions: which RNA is it? Retrovirology, 5, 55.
31. Kozak,S.L., Marin,M., Rose,K.M., Bystrom,C. and Kabat,D. (2006) The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem., 281, 29105-29119.
32. Goila-Gaur,R., Khan,M.A., Miyagi,E. and Strebel,K. (2009) Differential sensitivity of 'old' versus 'new' APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol., 83, 1156-1160.
33. Li,J., Chen,Y., Li,M., Carpenter,M.A., McDougle,R.M., Luengas,E.M., Macdonald,P.J., Harris,R.S. and Mueller,J.D. (2014) APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J. Mol. Biol., 426, 1296-1307.
34. Cen,S., Peng,Z.G., Li,X.Y., Li,Z.R., Ma,J., Wang,Y.M., Fan,B., You,X.F., Wang,Y.P., Liu,F. et al. (2010) Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem., 285, 16546-16552.
35. Luo,K., Xiao,Z., Ehrlich,E., Yu,Y., Liu,B., Zheng,S. and Yu,X.F. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A., 102, 11444-11449.
36. Wedekind,J.E., Gillilan,R., Janda,A., Krucinska,J., Salter,J.D., Bennett,R.P., Raina,J. and Smith,H.C. (2006) Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem., 281, 38122-38126.
37. Iwatani,Y., Takeuchi,H., Strebel,K. and Levin,J.G. (2006) Biochemical activities of highly puified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol., 80, 5992-6002.
38. Chaurasiya,K.R., McCauley,M.J., Wang,W., Qualley,D.F., Wu,T., Kitamura,S., Geertsema,H., Chan,D.S., Hertz,A., Iwatani,Y. et al. (2014) Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem., 6, 28-33.
39. McDougall,W.M., Okany,C. and Smith,H.C. (2011) Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J. Biol. Chem., 286, 30655-30661.
40. Chen,K.M., Martemyanova,N., Lu,Y., Shindo,K., Matsuo,H. and Harris,R.S. (2007) Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Letts., 581, 4761-4766.
41. Holden,L.G., Prochnow,C., Chang,Y.P., Bransteitter,R., Chelico,L., Sen,U., Stevens,R.C., Goodman,M.F. and Chen,X.S. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature, 456, 121-124.
42. Li,X., Ma,J., Zhang,Q., Zhou,J., Yin,X., Zhai,C., You,X., Yu,L., Guo,F., Zhao,L. et al. (2011) Functional analysis of the two cytidine deaminase domains in APOBEC3G. Virology, 414, 130-136.
43. Navarro,F., Bollman,B., Chen,H., Konig,R., Yu,Q., Chiles,K. and Landau,N.R. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology, 333, 374-386.
44. Smith,H.C. (2007) Measuring editing activity and identifying cytidine-to-uridine mRNA editing factors in cells and biochemical isolates. Methods Enzymol., 424, 389-416.
45. Chodosh,L.A. (1996) UV crosslinking of proteins to nucleic acids. Current Protocols in Molecular Biology. John Wiley & Sons, Inc, 12.5.1-12.5.8.
46. Hicke,B.J., Willis,M.C., Koch,T.H. and Cech,T.R. (1994) Telomeric protein-DNA point contacts identified by photo-cross-linking using 5-bromodeoxyuridine. Biochemistry, 33, 3364-3373.
47. Urlaub,H., Hartmuth,K., Kostka,S., Grelle,G. and Luhrmann,R. (2000) A general approach for identification of RNA-protein cross-linking sites within native human spliceosomal small nuclear ribonucleoproteins (snRNPs). Analysis of RNA-protein contacts in native U1 and U4/U6.U5 snRNPs. J. Biol. Chem., 275, 41458-41468.
48. Shandilya,S.M., Nalam,M.N., Nalivaika,E.A., Gross,P.J., Valesano,J.C., Shindo,K., Li,M., Munson,M., Royer,W.E., Harjes,E. et al. (2010) Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure, 18, 28-38.
49. Arnold,K., Bordoli,L., Kopp,J. and Schwede,T. (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics, 22, 195-201.
50. Thy Pymol Molecular Graphics System. Version 1.7.4 Schrödinger, LLC.
51. Chelico,L., Pham,P. and Goodman,M.F. (2009) Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Philos. Trans. R Soc. Lond. B Biol. Sci., 364, 583-593.
52. Chelico,L., Prochnow,C., Erie,D.A., Chen,X.S. and Goodman,M.F. (2010) Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem., 285, 16195-16205.
53. Nowarski,R., Britan-Rosich,E., Shiloach,T. and Kotler,M. (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol., 15, 1059-1066.
54. Belanger,K., Savoie,M., Rosales Gerpe,M.C., Couture,J.F. and Langlois,M.A. (2013) Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res., 41, 7438-7452.
55. Chelico,L., Sacho,E.J., Erie,D.A. and Goodman,M.F. (2008) A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J. Biol. Chem., 283, 13780-13791.
56. Huthoff,H., Autore,F., Gallois-Montbrun,S., Fraternali,F. and Malim,M.H. (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog., 5, e1000330.
57. Shlyakhtenko,L.S., Lushnikov,A.Y., Li,M., Lackey,L., Harris,R.S. and Lyubchenko,Y.L. (2011) Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem., 286, 3387-3395.
58. Shlyakhtenko,L.S., Lushnikov,A.Y., Miyagi,A., Li,M., Harris,R.S. and Lyubchenko,Y.L. (2013) Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J. Struct. Biol., 184, 217-225.
59. Jarmuz,A., Chester,A., Bayliss,J., Gisbourne,J., Dunham,I., Scott,J. and Navaratnam,N. (2002) An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22. Genomics, 79, 285-296.
60. Kouno,T., Luengas,E.M., Shigematsu,M., Shandilya,S.M., Zhang,J., Chen,L., Hara,M., Schiffer,C.A., Harris,R.S. and Matsuo,H. (2015) Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol., 22, 485-491.
61. Wedekind,J.E., Dance,G.S., Sowden,M.P. and Smith,H.C. (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19, 207-216.
62. LaRue,R.S., Andresdottir,V., Blanchard,Y., Conticello,S.G., Derse,D., Emerman,M., Greene,W.C., Jonsson,S.R., Landau,N.R., Lochelt,M. et al. (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol., 83, 494-497.
63. Belanger,K. and Langlois,M.A. (2015) RNA-binding residues in the N-terminus of APOBEC3G influence its DNA sequence specificity and retrovirus restriction efficiency. Virology, 483, 141-148.
64. Chen,K.M., Harjes,E., Gross,P.J., Fahmy,A., Lu,Y., Shindo,K., Harris,R.S. and Matsuo,H. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature, 452, 116-119.
65. Feng,Y. and Chelico,L. (2011) Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J. Biol. Chem., 286, 11415-11426.
66. Shindo,K., Li,M., Gross,P.J., Brown,W.L., Harjes,E., Lu,Y., Matsuo,H. and Harris,R.S. (2012) A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G. Biology, 1, 260-276.
67. Furukawa,A., Nagata,T., Matsugami,A., Habu,Y., Sugiyama,R., Hayashi,F., Kobayashi,N., Yokoyama,S., Takaku,H. and Katahira,M. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J., 28, 440-451.
68. Bennett,R.P., Salter,J.D., Liu,X., Wedekind,J.E. and Smith,H.C. (2008) APOBEC3G subunits self-associate via the C-terminal deaminase domain. J. Biol. Chem., 283, 33329-33336.
69. Salter,J.D., Krucinska,J., Raina,J., Smith,H.C. and Wedekind,J.E. (2009) A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function. Biochemistry, 48, 10685-10687.
70. Lavens,D., Peelman,F., Van der Heyden,J., Uyttendaele,I., Catteeuw,D., Verhee,A., Van Schoubroeck,B., Kurth,J., Hallenberger,S., Clayton,R. et al. (2010) Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res., 38, 1902-1912.